Top

The European Journal of Health Economics

Published in:

Open Access 01-06-2019 | Original Paper

Cost-of-illness studies in nine Central and Eastern European countries

Authors: Valentin Brodszky, Zsuzsanna Beretzky, Petra Baji, Fanni Rencz, Márta Péntek, Alexandru Rotar, Konstantin Tachkov, Susanne Mayer, Judit Simon, Maciej Niewada, Rok Hren, László Gulácsi

Published in: The European Journal of Health Economics | Special Issue 1/2019

Abstract

Background

To date, a multi-country review evaluating the cost-of-illness (COI) studies from the Central and Eastern European (CEE) region has not yet been published. Our main objective was to provide a general description about published COI studies from CEE.

Methods

A systematic search was performed between 1 January 2006 and 1 June 2017 in Medline, EMBASE, The Cochrane Library, CINAHL, and Web of Science to identify all relevant COI studies from nine CEE countries. COI studies reporting costs without any restrictions by age, co-morbidities, or treatment were included. Methodology, publication standards, and cost results were analysed.

Results

We identified 58 studies providing 83 country-specific COI results: Austria (n = 9), Bulgaria (n = 16), Croatia (n = 3), the Czech Republic (n = 10), Hungary (n = 24), Poland (n = 11), Romania (n = 3), Slovakia (n = 3), and Slovenia (n = 4). Endocrine, nutritional, and metabolic diseases (18%), neoplasms (12%), infections (11%), and neurological disorders (11%) were the most frequently studied clinical areas, and multiple sclerosis was the most commonly studied disease. Overall, 57 (98%) of the studies explicitly stated the source of resource use data, 45 (78%) the study perspective, 34 (64%) the costing method, and 24 (58%) reported at least one unit costs. Regardless of methodological differences, a positive relationship was observed between costs of diseases and countries’ per capita GDP.

Conclusions

Cost-of-illness studies varied considerably in terms of methodology, publication practice, and clinical areas. Due to these heterogeneities, transferability of the COI results is limited across Central and Eastern European countries.

Available only for authorised users

Drummond, M., Sculpher, M., Torrance, G.: Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University PressOxford University Press, Oxford (2005)

Tarricone, R.: Cost-of-illness analysis. What room in health economics? Health Policy 77(1), 51–63 (2006). https://doi.org/10.1016/j.healthpol.2005.07.016 CrossRefPubMed

Gulacsi, L., Rotar, A.M., Niewada, M., Loblova, O., Rencz, F., Petrova, G., Boncz, I., Klazinga, N.S.: Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. Eur. J. Health Econ. 15(Suppl 1), S13–S25 (2014). https://doi.org/10.1007/s10198-014-0590-8 CrossRefPubMed

Boncz, I., Sebestyen, A.: Financial deficits in the health services of the UK and Hungary. Lancet 368(9539), 917–918 (2006). https://doi.org/10.1016/S0140-6736(06)69369-0 CrossRefPubMed

Feig, C., Cheung, K.L., Hiligsmann, M., Evers, S., Simon, J., Mayer, S.: Best-worst scaling to assess the most important barriers and facilitators for the use of health technology assessment in Austria. Expert Rev. Pharmacoecon. Outcomes Res. (2017). https://doi.org/10.1080/14737167.2017.1375407 CrossRefPubMed

Larg, A., Moss, J.R.: Cost-of-illness studies: a guide to critical evaluation. PharmacoEconomics 29(8), 653–671 (2011). https://doi.org/10.2165/11588380-000000000-00000 CrossRefPubMed

Jacobs, P., Ohinmaa, A., Brady, B.: Providing systematic guidance in pharmacoeconomic guidelines for analysing costs. Pharmacoeconomics 23(2), 143–153 (2005)CrossRefPubMed

Brouwer, W., Rutten, F., Koopmanschap, M.: Costing in economic evaluations. In: Drummond, M., McGuire, A. (eds.) Economic evaluations in health care: merging theory with practice. Oxford University Press, New York (2001)

Angelis, A., Tordrup, D., Kanavos, P.: Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy 119(7), 964–979 (2015). https://doi.org/10.1016/j.healthpol.2014.12.016 CrossRefPubMed

10.

Onukwugha, E., McRae, J., Kravetz, A., Varga, S., Khairnar, R., Mullins, C.D.: Cost-of-illness studies: an updated review of current methods. PharmacoEconomics 34(1), 43–58 (2016). https://doi.org/10.1007/s40273-015-0325-4 CrossRefPubMed

11.

Clabaugh, G., Ward, M.M.: Cost-of-illness studies in the United States: a systematic review of methodologies used for direct cost. Value Health 11(1), 13–21 (2008). https://doi.org/10.1111/j.1524-4733.2007.002 CrossRefPubMed

12.

Oliva-Moreno, J., Trapero-Bertran, M., Pena-Longobardo, L.M., Del Pozo-Rubio, R.: The valuation of informal care in cost-of-illness studies: a systematic review. PharmacoEconomics 35(3), 331–345 (2017). https://doi.org/10.1007/s40273-016-0468-y CrossRefPubMed

13.

Mayer, S., Kiss, N., Laszewska, A., Simon, J.: Costing evidence for health care decision-making in Austria: a systematic review. PLoS One 12(8), e0183116 (2017). https://doi.org/10.1371/journal.pone.0183116 CrossRefPubMedPubMedCentral

14.

Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G.: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6(7), e1000097 (2009). https://doi.org/10.1371/journal.pmed.1000097 CrossRefPubMedPubMedCentral

15.

Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A.H., Mauskopf, J., Loder, E., Force, C.T.: Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health 16(2), e1–e5 (2013). https://doi.org/10.1016/j.jval.2013.02.010 CrossRefPubMed

16.

Eurostat: ECU/EUR exchange rates versus national currencies. http://ec.europa.eu/eurostat/estat-navtree-portlet-prod/NodeInfoServices?lang=en&code=tec00033 Accessed 19 Sep 2017

17.

International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10 Version:2016) (2016). http://apps.who.int/classifications/icd10/browse/2016/en Accessed 21 Jul 2017

18.

Georgieva, V.: Pharmacoeconomic evaluation of surgical and endovascular therapy of brain aneurism. PhD thesis, Medical University of Sofia (2015)

19.

Glogovska, P., Ivanov, Y., Hristova, P., Pavlov, P., Popova, T.E.B.: Pharmacoeconomic evaluation of the ambulatory and hospital cost of therapy of patients with community acquired respiratory tract infections. Thorasis Med. 2(3), 52–56 (2010)

20.

Ivanova, Z., Veleva, N., Glogovska, P., Pavlov, P., Popova, T., Ivanov, Y.: Hospital therapy cost of patients with asthma. MEDINFO 14(12), 28–31 (2014)

21.

Kyuchukov, N., Yanev, N., Krachunov, I., Ivanova, Z., Pavlov, P., Popova, T., Glogovska, P., Hristova, P., Ivanov, Y.: Evaluation of COPD cost for patients on home oxygen therapy. Thorasic Med. 7(4), 50–56 (2015)

22.

Todorova, K.: Pharmacoeconomic analysis of the gestational diabetes therapy during pregnancy. PhD thesis, Medical University of Sofia (2007)

23.

Blahova Dusankova, J., Kalincik, T., Dolezal, T., Kobelt, G., Havrdova, E.: Cost of multiple sclerosis in the Czech Republic: the COMS study. Mult. Scler. 18(5), 662–668 (2012). https://doi.org/10.1177/1352458511424422 CrossRefPubMed

24.

Kobelt, G., Berg, J., Lindgren, P., Plesnilla, C., Baumhackl, U., Berger, T., Kolleger, H., Vass, K.: Costs and quality of life of multiple sclerosis in Austria. Eur. J. Health Econ. 7(Suppl 2), S14–S23 (2006). https://doi.org/10.1007/s10198-006-0382-x CrossRefPubMed

25.

Szmurlo, D., Fundament, T., Ziobro, M., Kruntoradova, K., Dolezal, T., Glogowski, C.: Costs of multiple sclerosis—extrapolation of Czech data to Polish patients. Expert Rev. Pharmacoecon. Outcomes Res. 14(3), 451–458 (2014). https://doi.org/10.1586/14737167.2014.906305 CrossRef

26.

Pentek, M., Harangozo, J., Egerhazi, A., Kelemen, O., Gulacsi, L., Baji, P., Mattyassy, A., Erdelyi, R., Lehoczky, S., Orlewska, E., Vartokne Hever, N., Ferencz, A., Brodszky, V.: Health related quality of life and disease burden of patients with schizophrenia in Hungary. Psychiatr. Hung. 27(1), 4–17 (2012)PubMed

27.

Jakubczyk, M., Lipka, I., Paweska, J., Niewada, M., Rdzanek, E., Zaletel, J., Ramirez de Arellano, A., Dolezal, T., Chekorova Mitreva, B., Nagy, B., Petrova, G., Saric, T., Yfantopoulos, J., Czech, M.: Cost of severe hypoglycaemia in nine European countries. J. Med. Econ. 19(10), 973–982 (2016). https://doi.org/10.1080/13696998.2016.1188823 CrossRefPubMed

28.

Lopez-Bastida, J., Linertova, R., Oliva-Moreno, J., Posada-de-la-Paz, M., Serrano-Aguilar, P., Kanavos, P., Taruscio, D., Schieppati, A., Iskrov, G., Baji, P., Delgado, C., von der Schulenburg, J.M., Persson, U., Chevreul, K., Fattore, G., Network, B.-R.R.: Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe. Eur J Health Econ 17(Suppl 1), 99–108 (2016). https://doi.org/10.1007/s10198-016-0788-z CrossRefPubMed

29.

Pentek, M., Gulacsi, L., Brodszky, V., Baji, P., Boncz, I., Pogany, G., Lopez-Bastida, J., Linertova, R., Oliva-Moreno, J., Serrano-Aguilar, P., Posada-de-la-Paz, M., Taruscio, D., Iskrov, G., Schieppati, A., von der Schulenburg, J.M., Kanavos, P., Chevreul, K., Persson, U., Fattore, G., Network, B.-R.R.: Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. Eur J Health Econ 17(Suppl 1), 89–98 (2016). https://doi.org/10.1007/s10198-016-0787-0 CrossRefPubMed

30.

Pentek, M., Gulacsi, L., Rozsa, C., Simo, M., Iljicsov, A., Komoly, S., Brodszky, V.: Health status and costs of ambulatory patients with multiple sclerosis in Hungary. Ideggyogy Sz 65(9–10), 316–324 (2012)PubMed

31.

Nerat, T., Kos, M.: Burden of Type 2 Diabetes from the Healthcare Payer Perspective in Slovenia/Breme Sladkorne Bolezni Tipa 2 S Stališča Plačnika Zdravstvenega Varstva V Sloveniji. Slov. J. Public Health (2013). https://doi.org/10.2478/sjph-2013-0018 CrossRef

32.

Valov, V., Doneva, M., Borisova, A.M., Tankova, T., Czech, M., Manova, M., Savova, A., Peikova, L., Petrova, G.: Regional differences in diabetic patients’ pharmacotherapy in Bulgaria. Eur Rev Med Pharmacol Sci 18(10), 1499–1506 (2014)PubMed

33.

von Campenhausen, S., Winter, Y., Gasser, J., Seppi, K., Reese, J.P., Pfeiffer, K.P., Geiger-Gritsch, S., Botzel, K., Siebert, U., Oertel, W.H., Dodel, R., Poewe, W.: Cost of illness and health service patterns in Morbus Parkinson in Austria. Wien. Klin. Wochenschr. 121(17–18), 574–582 (2009). https://doi.org/10.1007/s00508-009-1223-6 CrossRef

34.

Winter, Y., von Campenhausen, S., Brozova, H., Skoupa, J., Reese, J.P., Botzel, K., Eggert, K., Oertel, W.H., Dodel, R., Ruzicka, E.: Costs of Parkinson’s disease in eastern Europe: a Czech cohort study. Parkinsonism Relat Disord 16(1), 51–56 (2010). https://doi.org/10.1016/j.parkreldis.2009.07.005 CrossRefPubMed

35.

Ersek, K., Kovacs, T., Wimo, A., Karpati, K., Brodszky, V., Pentek, M., Jonsson, L., Gustavsson, A., McDaid, D., Kenigsberg, P.A., Valtonen, H., Gulacsi, L.: Costs of dementia in Hungary. J Nutr Health Aging 14(8), 633–639 (2010)CrossRefPubMed

36.

Holmerova, I., Hort, J., Rusina, R., Wimo, A., Steffl, M.: Costs of dementia in the Czech Republic. Eur J Health Econ (2016). https://doi.org/10.1007/s10198-016-0842-x CrossRefPubMed

37.

Stambu, I., Stoicescu, I.P.: Estimation of direct medical costs of chronic obstructive pulmonary disease over 12 months. Pneumologia 62(2), 86–92 (2013)PubMed

38.

DALYs G, Collaborators, H.: Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390(10100), 1260–1344 (2017). https://doi.org/10.1016/s0140-6736(17)32130-x CrossRef

39.

Rencz, F., Gulacsi, L., Drummond, M., Golicki, D., Prevolnik Rupel, V., Simon, J., Stolk, E.A., Brodszky, V., Baji, P., Zavada, J., Petrova, G., Rotar, A., Pentek, M.: EQ-5D in Central and Eastern Europe: 2000–2015. Qual. Life Res. 25(11), 2693–2710 (2016). https://doi.org/10.1007/s11136-016-1375-6 CrossRefPubMed

40.

Brodszky, V., Varga, P., Gimesi-Orszagh, J., Fadgyas-Freyler, P., Boncz, I., Nyirady, P., Riesz, P., Baji, P., Pentek, M., Rencz, F., Gulacsi, L.: Long-term costs and survival of prostate cancer: a population-based study. Int. Urol. Nephrol. 49(10), 1707–1714 (2017). https://doi.org/10.1007/s11255-017-1669-9 CrossRefPubMed

41.

Inotai, A., Abonyi-Tóth, Z., Rokszin, G., Vokó, Z.: Prognosis, cost, and occurrence of colorectal, lung, breast, and prostate cancer in hungary. Value Health Reg Issues 7, 1–8 (2015). https://doi.org/10.1016/j.vhri.2015.03.020 CrossRefPubMed

42.

European Observatory on Health Systems and Policies: Health system reviews (HiT series) http://www.euro.who.int/en/about-us/partners/observatory/publications/health-system-reviews-hits/full-list-of-country-hits. Accessed 03 Nov 2018

43.

Seuring, T., Archangelidi, O., Suhrcke, M.: The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics 33(8), 811–831 (2015). https://doi.org/10.1007/s40273-015-0268-9 CrossRefPubMedPubMedCentral

44.

Zhao, F.L., Xie, F., Hu, H., Li, S.C.: Transferability of indirect cost of chronic disease: a systematic review and meta-analysis. Pharmacoeconomics 31(6), 501–508 (2013). https://doi.org/10.1007/s40273-013-0053-6 CrossRefPubMed

45.

Gao, L., Hu, H., Zhao, F.L., Li, S.C.: Can the direct medical cost of chronic disease be transferred across different countries? Using cost-of-illness studies on type 2 diabetes, epilepsy and schizophrenia as examples. PLoS One 11(1), e0147169 (2016). https://doi.org/10.1371/journal.pone.0147169 CrossRefPubMedPubMedCentral

46.

Brouwer, W., Rutten, F., Koopmanschap, M.: Costing in economic evaluations, chapter 4 p. 68-94. In: Drummond, M., McGuire, A. (eds.) Economic Evaluation in Health Care. OHE Oxford University Press, Oxford (2001)

47.

Mayer, S., Kiss, N., Laszewska, A., Simon, J.: Health economic costing methods and reporting in Austria. Value Health 19(7), A363 (2016)CrossRef

48.

DHE Unit Cost Online Database: Cost Collection from Existing Studies. Version 2.2/2017. Vienna: Department of Health Economics (DHE), Center for Public Health, Medical University of Vienna (2017)

49.

Rotar, A.M., Preda, A., Löblová, O., Benkovic, Zawodnik, V.S., Gulacsi, L., Niewada, M., Boncz, I., Petrova, G., Dimitrova, M., Klazinga, N.: Rationalizing the introduction and use of pharmaceutical products: the role of managed entry agreements in Central and Eastern European countries, 2018, Health Policy accepted for publication (2018)

50.

Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. 2013. EMiNet, Brussels, Belgium. http://eprints.lse.ac.uk/50513/1/__Libfile_repository_Content_Ferrario%2C%20A_Ferrario_Managed_%20entry_%20agreements_2013_Ferrario_Managed_%20entry_%20agreements_2013.pdf. Accessed 02 Nov 2018

51.

Nixon, J., Rice, S., Drummond, M., Boulenger, S., Ulmann, P., de Pouvourville, G.: Guidelines for completing the EURONHEED transferability information checklists. Eur. J. Health Econ. 10(2), 157–165 (2009). https://doi.org/10.1007/s10198-008-0115-4 CrossRefPubMed

52.

de Pouvourville, G., Ulmann, P., Nixon, J., Boulenger, S., Glanville, J., Drummond, M.: The diffusion of health economics knowledge in Europe: the EURONHEED (European Network of Health Economics Evaluation Database) project. Pharmacoeconomics 23(2), 113–120 (2005)CrossRefPubMed

53.

Drummond, M., Brown, R., Fendrick, A.M., Fullerton, P., Neumann, P., Taylor, R., Barbieri, M., Force, I.T.: Use of pharmacoeconomics information–report of the ISPOR task force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health 6(4), 407–416 (2003)CrossRefPubMed

54.

Barbieri, M., Drummond, M., Rutten, F., Cook, J., Glick, H.A., Lis, J., Reed, S.D., Sculpher, M., Severens, J.L., Force, I.G.R.P.E.D.T.T.: What do international pharmacoeconomic guidelines say about economic data transferability? Value Health 13(8), 1028–1037 (2010). https://doi.org/10.1111/j.1524-4733.2010.00771.x CrossRefPubMed

55.

Mandrik, O., Knies, S., Kalo, Z., Severens, J.L.: Reviewing transferability in economic evaluations originating from Eastern Europe. Int. J. Technol. Assess. Health Care 31(6), 434–441 (2015). https://doi.org/10.1017/S0266462315000677 CrossRefPubMedPubMedCentral

56.

Gulacsi, L., Rencz, F., Pentek, M., Brodszky, V., Lopert, R., Hever, N.V., Baji, P.: Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries. Eur. J. Health Econ. 15(Suppl 1), S27–S34 (2014). https://doi.org/10.1007/s10198-014-0591-7 CrossRefPubMed

57.

Drummond, M.F., Sculpher, M.J., Torrance, G.W., O’Brien, B.J., Stoddart, G.L.: Methods for the Economic Evaluation of Health care Programmes, 4th edn. Oxford University Press, Oxford (2015)

58.

Grabmeier-Pfistershammer, K., Rieger, A., Schrock, T., Schlag, M.: Economic burden of late presentation in HIV disease in Austria: a comparison of the initial costs imposed by advanced HIV disease vs. non-late presentation. Wien Klin Wochenschr 125(13-14), 402–407 (2013). https://doi.org/10.1007/s00508-013-0392-5 CrossRefPubMed

59.

Leal, J., Luengo-Fernandez, R., Sullivan, R., Witjes, J.A.: Economic burden of bladder cancer across the European union. Eur. Urol. 69(3), 438–447 (2016). https://doi.org/10.1016/j.eururo.2015.10.024 CrossRefPubMed

60.

Prast, J., Oppelt, P., Shamiyeh, A., Shebl, O., Brandes, I., Haas, D.: Costs of endometriosis in Austria: a survey of direct and indirect costs. Arch. Gynecol. Obstet. 288(3), 569–576 (2013). https://doi.org/10.1007/s00404-013-2793-0 CrossRefPubMed

61.

Willich, S.N., Nocon, M., Kulig, M., Jaspersen, D., Labenz, J., Meyer-Sabellek, W., Stolte, M., Lind, T., Malfertheiner, P.: Cost-of-disease analysis in patients with gastro-oesophageal reflux disease and Barrett’s mucosa. Aliment. Pharmacol. Ther. 23(3), 371–376 (2006). https://doi.org/10.1111/j.1365-2036.2006.02763.x CrossRefPubMed

62.

Dimai, H.P., Redlich, K., Schneider, H., Siebert, U., Viernstein, H., Mahlich, J.: Direct and indirect costs of fractures due to osteoporosis in Austria. Gesundheitswesen 74(10), e90–e98 (2012). https://doi.org/10.1055/s-0031-1301274 CrossRefPubMed

63.

Wagner, E.: Direct costs of osteoarthritis. Wien. Med. Wochenschr. 161(1–2), 44–52 (2011). https://doi.org/10.1007/s10354-010-0858-2 CrossRefPubMed

64.

Wagner, E.: Costs of non-specific low back pain in Austria. Wien. Med. Wochenschr. 162(5–6), 92–98 (2012). https://doi.org/10.1007/s10354-011-0050-3 CrossRefPubMed

65.

Angelis, A., Kanavos, P., Lopez-Bastida, J., Linertova, R., Oliva-Moreno, J., Serrano-Aguilar, P., Posada-de-la-Paz, M., Taruscio, D., Schieppati, A., Iskrov, G., Brodszky, V., von der Schulenburg, J.M., Chevreul, K., Persson, U., Fattore, G., Network, B.-R.R.: Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe. Eur. J. Health Econ. 17(Suppl 1), 31–42 (2016). https://doi.org/10.1007/s10198-016-0783-4 CrossRefPubMedPubMedCentral

66.

Cavazza, M., Kodra, Y., Armeni, P., De Santis, M., Lopez-Bastida, J., Linertova, R., Oliva-Moreno, J., Serrano-Aguilar, P., Posada-de-la-Paz, M., Taruscio, D., Schieppati, A., Iskrov, G., Gulacsi, L., von der Schulenburg, J.M., Kanavos, P., Chevreul, K., Persson, U., Fattore, G., Network, B.-R.R.: Social/economic costs and quality of life in patients with haemophilia in Europe. Eur. J. Health Econ. 17(Suppl 1), 53–65 (2016). https://doi.org/10.1007/s10198-016-0785-2 CrossRefPubMed

67.

Cavazza, M., Kodra, Y., Armeni, P., De Santis, M., Lopez-Bastida, J., Linertova, R., Oliva-Moreno, J., Serrano-Aguilar, P., Posada-de-la-Paz, M., Taruscio, D., Schieppati, A., Iskrov, G., Pentek, M., von der Schulenburg, J.M., Kanavos, P., Chevreul, K., Persson, U., Fattore, G., Network, B.-R.R.: Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. Eur. J. Health Econ. 17(Suppl 1), 19–29 (2016). https://doi.org/10.1007/s10198-016-0782-5 CrossRefPubMed

68.

Chevreul, K., Michel, M., Brigham, K.B., Lopez-Bastida, J., Linertova, R., Oliva-Moreno, J., Serrano-Aguilar, P., Posada-de-la-Paz, M., Taruscio, D., Schieppati, A., Iskrov, G., Pentek, M., von der Schulenburg, J.M., Kanavos, P., Persson, U., Fattore, G., Network, B.-R.R.: Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe. Eur. J. Health Econ. 17(Suppl 1), 7–18 (2016). https://doi.org/10.1007/s10198-016-0781-6 CrossRefPubMed

69.

Iskrov, G., Astigarraga, I., Stefanov, R., Lopez-Bastida, J., Linertova, R., Oliva-Moreno, J., Serrano-Aguilar, P., Posada-de-la-Paz, M., Schieppati, A., Taruscio, D., Pentek, M., von der Schulenburg, J.M., Kanavos, P., Chevreul, K., Persson, U., Fattore, G., Network, B.-R.R.: Social/economic costs and health-related quality of life in patients with histiocytosis in Europe. Eur. J. Health Econ. 17(Suppl 1), 67–78 (2016). https://doi.org/10.1007/s10198-016-0790-5 CrossRefPubMed

70.

Iskrov, G.G., Stefanov, R.S., Lopez-Bastida, J., Linertova, R., Oliva-Moreno, J., Serrano-Aguilar, P., Network, B.-R.R.: Economic burden and health-related quality of life of patients with cystic fibrosis in Bulgaria. Folia Med (Plovdiv) 57(1), 56–64 (2015). https://doi.org/10.1515/folmed-2015-0020 CrossRef

71.

Bencina, G., Buljan, M., Situm, M., Stevanovic, R., Benkovic, V.: Health and economic burden of skin melanoma in croatia—cost-of-illness study. Acta Dermatovenerol. Croat. 25(1), 1–7 (2017)PubMed

72.

Klimeš, J., Vocelka, M., Šedová, L., Doležal, T., Mlčoch, T., Petříková, A., Vlček, J.: Medical and productivity costs of rheumatoid arthritis in The Czech Republic: cost-of-illness study based on disease severity. Value in Health Regional Issues 4, 75–81 (2014). https://doi.org/10.1016/j.vhri.2014.07.004 CrossRefPubMed

73.

Maresova, P., Zahalkova, V.: The economic burden of the care and treatment for people with Alzheimer’s disease: the outlook for the Czech Republic. Neurol Sci 37(12), 1917–1922 (2016). https://doi.org/10.1007/s10072-016-2679-6 CrossRefPubMed

74.

Mlcoch, T., Klimes, J., Fila, L., Vavrova, V., Skalicka, V., Turnovec, M., Krulisova, V., Jircikova, J., Zemkova, D., Dedeckova, K.V., Bilkova, A., Fruhaufova, V., Homola, L., Friedmannova, Z., Drnek, R., Drevinek, P., Dolezal, T., Macek Jr., M.: Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study. Eur. J. Health Econ. 18(1), 73–82 (2017). https://doi.org/10.1007/s10198-015-0759-9 CrossRefPubMed

75.

Tichopad, A., Mullerova, J., Jackowska, T., Nemes, E., Pazdiora, P., Sloesen, B., Stefkovicova, M.: Cost burden of severe community-acquired rotavirus gastroenteritis requiring hospitalization in the Czech Republic, Slovakia, Poland, and Hungary: a retrospective patient chart review. Value Health Reg Issues 10, 53–60 (2016). https://doi.org/10.1016/j.vhri.2016.07.005 CrossRefPubMed

76.

Tichopad, A., Roberts, C., Gembula, I., Hajek, P., Skoczynska, A., Hryniewicz, W., Jahnz-Rozyk, K., Prymula, R., Solovic, I., Kolek, V.: Clinical and economic burden of community-acquired pneumonia among adults in the Czech Republic, Hungary, Poland and Slovakia. PLoS One 8(8), e71375 (2013). https://doi.org/10.1371/journal.pone.0071375 CrossRefPubMedPubMedCentral

77.

Balogh, O., Brodszky, V., Gulacsi, L., Heredi, E., Herszenyi, K., Jokai, H., Karpati, S., Baji, P., Remenyik, E., Szegedi, A., Hollo, P.: Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres. Eur. J. Health Econ. 15(Suppl 1), S101–S109 (2014). https://doi.org/10.1007/s10198-014-0599-z CrossRefPubMed

78.

Brodszky, V., Balint, P., Geher, P., Hodinka, L., Horvath, G., Koo, E., Pentek, M., Polgar, A., Sesztak, M., Szanto, S., Ujfalussy, I., Gulacsi, L.: Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol Int 30(2), 199–205 (2009). https://doi.org/10.1007/s00296-009-0936-1 CrossRefPubMed

79.

Chevreul, K., Gandre, C., Brigham, K.B., Lopez-Bastida, J., Linertova, R., Oliva-Moreno, J., Serrano-Aguilar, P., Posada-de-la-Paz, M., Taruscio, D., Schieppati, A., Iskrov, G., Gulacsi, L., von der Schulenburg, J.M., Kanavos, P., Persson, U., Fattore, G., Network, B.-R.R.: Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe. Eur. J. Health Econ. 17(Suppl 1), 43–52 (2016). https://doi.org/10.1007/s10198-016-0784-3 CrossRefPubMed

80.

Gulacsi, L., Majer, I., Boncz, I., Brodszky, V., Merkely, B., Maurovich, H.P., Karpati, K.: Health care costs of acute myocardial infarction in Hungary, 2003–2005. Orv. Hetil. 148(27), 1259–1266 (2007). https://doi.org/10.1556/OH.2007.28109 CrossRefPubMed

81.

Lopez-Bastida, J., Linertova, R., Oliva-Moreno, J., Serrano-Aguilar, P., Posada-de-la-Paz, M., Kanavos, P., Taruscio, D., Schieppati, A., Iskrov, G., Pentek, M., Delgado, C., von der Schulenburg, J.M., Persson, U., Chevreul, K., Fattore, G., Network, B.-R.R.: Social/economic costs and health-related quality of life in patients with scleroderma in Europe. Eur. J. Health Econ. 17(Suppl 1), 109–117 (2016). https://doi.org/10.1007/s10198-016-0789-y CrossRefPubMed

82.

Minier, T., Pentek, M., Brodszky, V., Ecseki, A., Karpati, K., Polgar, A., Czirjak, L., Gulacsi, L.: Cost-of-illness of patients with systemic sclerosis in a tertiary care centre. Rheumatology (Oxford) 49(10), 1920–1928 (2010). https://doi.org/10.1093/rheumatology/keq165 CrossRef

83.

Pentek, M., Bereczki, D., Gulacsi, L., Mikudina, B., Aranyi, Z., Juhos, V., Baji, P., Brodszky, V.: Survey of adults living with epilepsy in Hungary: health-related quality of life and costs. Ideggyogy Sz 66(7–8), 251–261 (2013)PubMed

84.

Rencz, F., Kovacs, A., Brodszky, V., Gulacsi, L., Nemeth, Z., Nagy, G.J., Nagy, J., Buzogany, I., Boszormenyi-Nagy, G., Majoros, A., Nyirady, P.: Cost of illness of medically treated benign prostatic hyperplasia in Hungary. Int. Urol. Nephrol. 47(8), 1241–1249 (2015). https://doi.org/10.1007/s11255-015-1028-7 CrossRefPubMed

85.

Tamas, G., Gulacsi, L., Bereczki, D., Baji, P., Takats, A., Brodszky, V., Pentek, M.: Quality of life and costs in Parkinson’s disease: a cross sectional study in Hungary. PLoS One 9(9), e107704 (2014). https://doi.org/10.1371/journal.pone.0107704 CrossRefPubMedPubMedCentral

86.

Pentek, M., Kobelt, G., Czirjak, L., Szekanecz, Z., Poor, G., Rojkovich, B., Polgar, A., Genti, G., Kiss, C.G., Brodszky, V., Majer, I., Gulacsi, L.: Costs of rheumatoid arthritis in Hungary. J. Rheumatol. 34(6), 1437 (2007)PubMed

87.

Czech, M., Rosinska, M., Rogalska, J., Staszewska, E., Stefanoff, P.: Costs of medically attended acute gastrointestinal infections: the polish prospective healthcare utilization survey. Value Health Reg Issues 2(2), 210–217 (2013). https://doi.org/10.1016/j.vhri.2013.06.011 CrossRefPubMed

88.

Dubas-Jakobczyk, K., Kocot, E., Seweryn, M., Koperny, M.: Production lost due to cervical cancer in Poland in 2012. Med. Pr. 67(3), 289–299 (2016). https://doi.org/10.13075/mp.5893.00378 CrossRefPubMed

89.

Jaworski, R., Jankowska, E.A., Ponikowski, P., Banasiak, W.: Costs of management of patients with coronary artery disease in Poland: the multicenter RECENT study. Pol. Arch. Med. Wewn. 122(12), 599–607 (2012)PubMed

90.

Kawalec, P.P., Malinowski, K.P.: The indirect costs of systemic autoimmune diseases, systemic lupus erythematosus, systemic sclerosis and sarcoidosis: a summary of 2012 real-life data from the Social Insurance Institution in Poland. Expert Rev Pharmacoecon Outcomes Res 15(4), 667–673 (2015). https://doi.org/10.1586/14737167.2015.1065733 CrossRefPubMed

91.

Lesniowska, J., Schubert, A., Wojna, M., Skrzekowska-Baran, I., Fedyna, M.: Costs of diabetes and its complications in Poland. Eur. J. Health Econ. 15(6), 653–660 (2014). https://doi.org/10.1007/s10198-013-0513-0 CrossRefPubMed

92.

Czech, M., Opolski, G., Zdrojewski, T., Dubiel, J.S., Wizner, B., Bolisega, D., Fedyk-Lukasik, M., Grodzicki, T.: The costs of heart failure in Poland from the public payer’s perspective. Polish programme assessing diagnostic procedures, treatment and costs in patients with heart failure in randomly selected outpatient clinics and hospitals at different levels of care: POLKARD. Kardiol Pol 71(3), 224–232 (2013). https://doi.org/10.5603/kp.2013.0032 CrossRefPubMed

93.

Stoicescu, I.P., Mihaescu, T., Azoicai, D., Arama, V., Balcu, I.: Preliminary assessment of Streptococcus pneumoniae, pneumonia, economical and clinical burden in Romania. Pneumologia 56(3), 118–123 (2007)PubMed

94.

Dzajkovska, B., Wertheimer, A.I., Mrhar, A.: The burden-of-illness study on osteoporosis in the Slovenian female population. Pharm. World Sci. 29(4), 404–411 (2007). https://doi.org/10.1007/s11096-007-9091-5 CrossRefPubMed

95.

Kopcsóné-Németh, I., Kertész, A., Strbák, B., Gulácsi, L.: A Clostridium difficile fertőzések költsége magyarországi kórházakban. Egészségügyi Gazdasági Szemle 13(2), 9–15 (2013)

96.

Ernstsson, O., Gyllensten, H., Alexanderson, K., Tinghog, P., Friberg, E., Norlund, A.: Cost of illness of multiple sclerosis—a systematic review. PLoS One 11(7), e0159129 (2016). https://doi.org/10.1371/journal.pone.0159129 CrossRefPubMedPubMedCentral

Title: Cost-of-illness studies in nine Central and Eastern European countries
Authors: Valentin Brodszky
Zsuzsanna Beretzky
Petra Baji
Fanni Rencz
Márta Péntek
Alexandru Rotar
Konstantin Tachkov
Susanne Mayer
Judit Simon
Maciej Niewada
Rok Hren
László Gulácsi
Publication date: 01-06-2019
Publisher: Springer Berlin Heidelberg
Published in: The European Journal of Health Economics / Issue Special Issue 1/2019
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-019-01066-x

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Cost-of-illness studies in nine Central and Eastern European countries

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Special Issue 1/2019

Validity and reliability of the 9-item Shared Decision Making Questionnaire (SDM-Q-9) in a national survey in Hungary

Patient experiences with outpatient care in Hungary: results of an online population survey

Patient and general population values for luminal and perianal fistulising Crohn’s disease health states

Patient-reported outcomes: opportunities and challenges in Central Europe

Determinants of the acceptability of health problems in different ages: exploring a new application of the EQ VAS

Subjective expectations regarding ageing: a cross-sectional online population survey in Hungary